INTRODUCTION
Bitter melon (Momordica charantia L.), a member of family Cucurbitaceae, is a woodbine that grows in tropical to temperate regions in Asia, including Indonesia and Japan. This plant is known as Pare (Indonesia) and Tsurureishi or Goya (Japan). This plant's immature, green fruit is a common vegetable in Indonesia and Japan ( Figure 1 ). Bitter melon has also been used as a traditional medicine in Indonesia to treat microbial infections and diabetes mellitus and is known as Jamu. Bitter melon contains many constituents: cucurbitane-type triterpenoids (e.g., momordicins, charantin, kuguacins, and karavilagenins) [1] [2] [3] [4] , phenolic compounds (e.g., gallic acid, tannic acid, caffeic acid, and p-coumaric acid), flavonoids (e.g., catechin and epicatechin) [5] [6] [7] , cucurbitane-type triterpene glycosides (e.g., momordicosides, karavilosides, and goyaglycosides) [8, 9] , steroidal glycosides, alkaloids, and polysaccharides. There are several reports investigating the efficacy of bitter melon for treating obesity, dyslipidemia, liver disease, and diabetes mellitus. A bitter melon extract was demonstrated to reduce fat deposition and body weight gain, which are early signs of obesity [10, 11] . A bitter melon extract was previously observed to attenuate high lipid levels in diabetic rats fed a highfat diet in a rat model of dyslipidemia [11] . Rats fed a bitter melon powder with cholesterol exhibited decreased hepatic total cholesterol and triglyceride levels [12] . The hepatoprotective activity of bitter melon extract may be related to its antioxidant ability to scavenge free radicals and reduce inflammation caused by noxious stimuli in the liver. Recent studies demonstrated that bitter melon can decrease oxidative stress in the liver by increasing the antioxidant activity of super oxide dismutase, glutathione peroxidase, and catalase [13, 14] . Furthermore, there
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have been reports about the antidiabetic and antihyperglycemic effects of bitter melon in several animal models [15] [16] [17] .
Nitric oxide (NO) is a pro-inflammatory mediator that plays crucial roles in signal transduction in response to inflammation, vasodilation, and neurotransmission [18] . NO kills bacteria and inhibits viral growth. However, NO causes tissue damage when it is synthesized in excess under a pathophysiological condition [19] . The production of NO in the cell is catalyzed by inducible nitric oxide synthase (iNOS), which can be induced in several cell types, including hepatocytes [20, 21] . The production of NO and the expression of iNOS gene in rat hepatocytes is induced by the pro-inflammatory cytokine interleukin (IL)-1β [22] .
Because there has not been significant study on the anti-inflammatory effects of bitter melon, we obtained extracts of Indonesian and Japanese bitter melons, fractionated them, and compared the effects of these fractions by monitoring NO production in hepatocytes.
Furthermore, we investigated the effect of bitter melon extracts and their fractions on the expression of genes encoding iNOS, pro-inflammatory cytokines, and chemokines.
MATERIALS AND METHODS

Plant materials and extraction
The immature fruits of bitter melon collected in Malang, East Java, Indonesia, and in Okinawa, Japan were purchased. After removing the seeds, the fruit was freeze-dried (kindly performed by Amino Up Co., Ltd., Sapporo, Japan). Voucher specimens of the dried fruit were deposited in the Ritsumeikan Herbarium of Pharmacognosy, Ritsumeikan University, under the code numbers RIN-MC-018 (Indonesia) and RIN-MC-019 (Japan).
The freeze-dried fruits of Indonesian and Japanese melon (80.07 g and 33.39 g) were extracted by absolute methanol (800 mL and 700 mL, respectively) under reflux at 60 °C for 1 h. This procedure was repeated, and the pooled methanol extracts were filtered and evaporated in vacuo. The resulting powder was dissolved in water and used as a bitter melon extract for the subsequent assays. As shown in Figure 2 , the extracts were fractionated by hydrophobicity into an ethyl acetate-soluble fraction (A, hydrophobic), an n-butanol-soluble fraction (B, amphipathic), and a water-soluble fraction (C, hydrophilic), according to the previously published method [23] . 
Primary cultured rat hepatocytes
Specific pathogen-free male Wistar rats were purchased from Charles River Laboratories Japan Inc. (Yokohama, Japan), housed at 21-23 °C under a 12-h light-dark cycle, with a γ-rayirradiated CRF-1 diet (Charles River Laboratories Japan Inc.) and water provided ad libitum.
The rats were acclimatized for a week. Hepatocytes were isolated from the rat livers by collagenase perfusion, resuspended in Williams' E (WE) medium (Sigma-Aldrich Corp., St.
Louis, MO, USA), and seeded at 1.2×10 6 cells per 35-mm diameter dish [24] . The hepatocytes were incubated at 37 °C overnight and then were treated with 1 nM rat IL-1β and an extract or fraction for 8 h. All the animal care and experimental procedures were carried out in accordance with the guidelines and laws of the Japanese Government and were approved by the Animal Care Committee of Ritsumeikan University, Biwako-Kusatsu Campus.
Determination of NO levels and lactate dehydrogenase (LDH) activity
The hepatocytes were treated with each extract or fraction in the presence or absence of 1 nM recombinant rat IL-1β for 8 h at 37 °C. The levels of nitrite (a stable metabolite of NO) in the medium were measured using the Griess method [25] . Briefly, 150 μL of the medium or sodium Inc., Japan). Whole cell extracts were prepared from the hepatocytes by cell lysis using 2%
(w/v) Triton X-100. Unless cytotoxicity was observed, the half-maximal inhibitory concentrations (IC50) were determined [26] .
Western blot analysis
The hepatocytes were treated with 1 nM IL-1β and an extract or fraction for 8 h at 37 °C, after which whole-cell lysates were prepared [27] . Briefly, the hepatocytes were lysed, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and electroblotted onto a Sequi-Blot membrane (Bio-Rad, Hercules, CA, USA). Immunostaining was performed using primary antibodies that were raised against rat iNOS (Thermo Fisher Scientific, Waltham, MA, USA) and rat β-tubulin (Cell Signaling Technology Inc., Danvers, MA, USA), followed by visualization with an Enhanced Chemiluminescence (ECL) Blotting Detection Reagent (GE Healthcare Biosciences Corp., Piscataway, NJ, USA).
Reverse transcription-polymerase chain reaction (RT-PCR)
The hepatocytes were treated with 1 nM IL-1β and/or an extract fraction for 4 h, after which the total RNA was prepared. The cDNA was reverse-transcribed in a strand-specific manner using an oligo (dT) primer for mRNA and a sense primer for the antisense transcripts (asRNAs) from the iNOS gene (Table 1) . PCR was performed with paired primers (Table 1 ). The levels of each transcript were measured in triplicate by quantitative PCR with a Thermal Cycler Dice
Real Time System (Takara Bio Inc.). The obtained values mRNA levels were normalized to the internal control, the elongation factor 1α (EF) [21] .
Statistical analysis
The results presented in the figures are representative of at least three independent experiments that yielded similar results. The values are presented as the means ± standard deviation (SD).
The differences were analyzed using Student's t-test. The statistical significance was set at P < 0.05 and P < 0.01 CCL20, chemokine C-C motif ligand 20; CX3CL1, chemokine C-X3-C motif ligand 1; EF, elongation factor 1α.
RESULTS
Preparation of extracts from Indonesian and Japanese bitter melon fruit
To analyze the pharmacological effects of bitter melon extracts, we collected the immature bitter melon fruit from Malang, Indonesia (2.00 kg), and Okinawa, Japan (25.58 kg). Seeds were removed from the fruit and freeze-dried to obtain 108.2 g (Indonesian) and 1.451 kg (Japanese) of the dried fruit. The resultant fruit was extracted with methanol and evaporated, with the resulting extracts used in subsequent assays.
Indonesian and Japanese bitter melon extracts suppress NO production in hepatocytes
We examined the effect of the methanol extracts of the freeze-dried Indonesian and Japanese bitter melon fruits on NO production in IL-1β-treated hepatocytes. When Indonesian or Japanese bitter melon extract (BME) was simultaneously added to the medium with IL-1β, both dose-dependently suppressed the levels of NO production ( Figure 3A) .
To monitor cytotoxicity, we measured the LDH activity in the medium. The LDH activity in the medium was very low, less than 5% ( Figure 3B ). These results suggest neither Indonesian nor Japanese BMEs were toxic to the hepatocyte at the concentration indicated. The IC50 values of Indonesian and Japanese BMEs were comparable (Table 2 ). Next, we investigated the effects of Indonesian and Japanese BMEs on iNOS protein expression. As shown in Figure 3C , western blot analysis indicated that Indonesian and Japanese BMEs dose-dependently decreased the iNOS protein expression in IL-1β-treated hepatocytes. These data suggest that Indonesian and Japanese BMEs have a similar activity with respect to the suppression of NO production and iNOS protein expression. 
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Fractionation of the bitter melon extracts
The extracts from the fruit of bitter melon were fractionated into three crude fractions based on hydrophobicity using ethyl acetate (fraction A), n-butanol (fraction B), and water (fraction C).
As shown in Table 2 , fraction C was the major fraction in the extracts from Indonesian and Japanese bitter melon. In general, fraction C contains hydrophilic constituents, such as sugars, peptides, and amino acids [23] .
Effects of fractions A and B of Indonesian and Japanese BMEs on NO production and iNOS protein expression
Next, we examined the effects of the fractions of Indonesian and Japanese BMEs on NO production in the presence of IL-1β in rat hepatocytes. Fractions A and B of Indonesian and Japanese BMEs decreased IL-1β-induced NO production. In contrast, fraction C from both BMEs did not affect NO production ( Figure 4 ). The LDH activity in the medium did not increase in response to the addition any of the fractions (data not shown), indicating that the fractions did not possess cytotoxicity. As shown in Table 2 , fraction A from both the Indonesian and Japanese BMEs exhibited comparable IC50 values. quantitative RT-PCR to estimate the levels of iNOS mRNA and asRNA. These levels were measured in triplicate (mean ± SD) and normalized to elongation factor 1α (EF) mRNA (internal control). The values in the presence of IL-1β alone were set at 100%. * P < 0.05 and ** P < 0.01 versus IL-1β alone.
Suppression of the expression of pro-inflammatory genes by bitter melon fraction A
The pro-inflammatory cytokines tumor necrosis factor (TNF)-α and IL-6 play key roles in inflammation, and chemokine C-C motif ligands 20 (CCL20) and C-X3-C motif ligand 1 (CX3CL1) are also involved in this process. The levels of these cytokine and chemokine mRNA levels were induced by IL-1β stimulation of rat hepatocytes [28] . Therefore, we examined whether fraction A of Indonesian and Japanese BMEs affects these mRNA levels in hepatocytes. When fraction A was added to the medium, the mRNA levels of these proinflammatory genes significantly decreased (Figure 6 ), suggesting that fraction A of Indonesian and Japanese BMEs suppresses the transcription of these mRNAs. Similar to the inhibition of NO production, the IC50 values for suppression of the mRNA induction were comparable (data not shown). These results indicate that fraction A of Indonesian and Japanese BMEs suppresses not only NO but also the cytokine/chemokine mRNA in a dose-dependent manner. 
DISCUSSION
In this study, we demonstrated that both extracts from Indonesian and Japanese bitter melon suppressed IL-1β-induced NO production in rat hepatocytes and that the ethyl acetate-soluble fraction A demonstrated the highest NO suppression activity. Fraction A of both BMEs revealed similar IC50 values (Table 2) . Because NO is a sensitive marker for monitoring antiinflammatory effects [26, 29] , our results suggest that bitter melon fraction A may have an antiinflammatory activity. In support of this finding, an aqueous extract of bitter melon was observed to reduce the serum NO concentration and protected the liver from damage induced by mitochondrial reactive oxygen species [30] .
The results of the present study indicated that the extracts and fraction A of Indonesian and Japanese bitter melon extracts suppressed the expression of iNOS protein in IL-1β-treated hepatocytes (Figures 3, 5) . Furthermore, fraction A of both BMEs decreased the levels of iNOS mRNA ( Figure 6 ). These results indicate that bitter melon fraction A likely inhibited the expression of the iNOS gene at the transcriptional level or later.
Fraction A of both Indonesian and Japanese BMEs decreased the levels of mRNAs encoding pro-inflammatory cytokines (TNF-α and IL-6) and chemokines (CCL20 and CX3CL1) (Figure 7 ). TNF-α and IL-6 are the key players involved in chronic liver injury and inflammation [31, 32] , and the expression of TNF-α mRNA is induced by IL-1β in rat hepatocytes [33] . Similar to Japanese herbal drugs and their constituents [34] , bitter melon fraction A suppressed the expression of TNF-α and IL-6 mRNA. CCL20 was identified as liver and activation-regulated chemokine/macrophage inflammatory protein-3α [35] . CX3CL1
increased with acute and chronic liver disease [36] . Therefore, the hydrophobic constituents of fraction A may exhibit anti-inflammatory effects by suppressing these pro-inflammatory cytokines and chemokines.
Bitter melon fruit contains low contents of many constituents [37] . Cucurbitane-type triterpenoids from bitter melon fruit are thought to possess anticancer, antioxidant, antidiabetic, and anti-hyperglycemic abilities [38] [39] [40] . Furthermore, steroidal glycosides from bitter melon fruit demonstrate potent antihyperglycemic and hypolipidemic activities [41] . Phenolic compounds and flavonoids from bitter melon fruit possess antioxidant, anti-inflammation, and immune-enhancing activities [42] [43] [44] . Our data suggest that hydrophobic constituents in fraction A (e.g., cucurbitane-type triterpenoids, flavonoids, and phenolic compounds) may be responsible for the observed anti-inflammatory effects. These hydrophobic constituents should be isolated to elucidate the anti-inflammatory effects of bitter melon.
In this study, we compared the pharmacological effects of bitter melon collected from two typical places of cultivation, Malang in Indonesia and Okinawa in Japan, where bitter melon is consumed as a traditional medicine and a vegetable. The IC50 value of Japanese BME was 1.99-fold higher than that of Indonesian BME, while the IC50 values of fraction A of Japanese and Indonesian BMEs were similar (Table 2 ). Comparing these IC50 values, fractions B and C are suggested to contain different composition and content of the constituents responsible for the suppression of NO production. The constituents may differ depending on climatic conditions, soil nutritional conditions, and harvest time. Further analysis of the constituents will clarify the differences in the IC50 values and constituents between Indonesian and Japanese BMEs.
Bitter melon fruit is usually cooked and eaten as a vegetable in Okinawa. The cooked bitter melon fruit is used as a healthy food. According to our results, searching literature up to date, there were no reports that health benefits are decreased by cooking procedures. We are currently purifying and analyzing the constituents in the bitter melon fruits. The effect by the cooking procedures on the pharmacological properties will be examined after the constituents are identified.
The recent clinical studies regarding the hypoglycemic effects of bitter melon are reviewed by Joseph and Jini [7] . However, the majority of these trials lacked proper controls or suffered from poor methodologies without baseline characterization [7] . Recently, Cortez-Navarrete et al. reported that administration of bitter melon fruit powder improved insulin secretion in type 2 diabetes mellitus patients [45] . More clinical trials are required to verify the pharmacological effects in the future.
CONCLUSION
Indonesian and Japanese bitter melon extracts exhibited similar activities for suppressing NO production and iNOS expression. The ethyl acetate-soluble fraction of Indonesian and Japanese
BMEs have comparable activities for suppressing the expression of the iNOS and proinflammatory cytokine/chemokine genes. These data suggest that hydrophobic constituents in the ethyl acetate-soluble fraction of BMEs, such as cucurbitane-type triterpenoids, may be responsible for the anti-inflammatory effects of bitter melon.
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Acknowledgments:
We thank Amino Up Co., Ltd. (Sapporo, Hokkaido, Japan) for freezedrying bitter melon samples and Ms. Noriko Kanazawa for her secretarial assistance.
Author contributions: DRD performed the experiments, data collection, statistical analysis, and drafted the manuscript as a graduate student. T. Okuyama and T. Okumura provided hepatocytes and advice regarding the experiments. MN and YI participated in the design of the study, supervised the study, and provided oversight in the drafting of the manuscript.
